IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc.'s Q·Score is 7.5/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 66% return on equity and 25% profit margins. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for IDXX is $724.50, based on ratings from 14 Wall Street analysts. This is 27.7% above the current price of $567.46. Price targets are forward-looking estimates and not guarantees of future performance.

IDEXX Laboratories, Inc. (IDXX) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 34.6×. The consensus analyst price target of $724.50 is 28% above the current price.

IDEXX Laboratories, Inc. is scheduled to report earnings in 2 days, on May 5, 2026.

IDEXX Laboratories, Inc. has a net profit margin of 24.6%, which is considered high and reflects strong pricing power. Its gross margin stands at 61.8%, indicating a high-margin business model.

IDEXX Laboratories, Inc. is reporting solid revenue growth of 14.3% year-over-year. Earnings are also growing at 17.9%, indicating improving profitability.

IDEXX Laboratories, Inc. has a debt-to-equity ratio of 0.61×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.23×, suggesting it should be monitored for near-term liquidity.